This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.
Summary
HIV treatment has undergone a revolution: daily oral pills are giving way to monthly or bimonthly injections, twice-yearly single-injection PrEP has transformed prevention, and for the first time, serious cure research is moving into clinical trials. In 2026, the frontier spans long-acting antiretrovirals, broadly neutralizing antibodies (bNAbs) capable of suppressing viral load without traditional ART, and mRNA-based vaccines aiming to eliminate the viral reservoir.
Long-Acting Injectable ART: Cabotegravir + Rilpivirine
Cabotegravir + rilpivirine (CAB+RPV, Cabenuva) was the first complete long-acting injectable HIV treatment regimen approved by the FDA in 2021. Rather than daily pills, patients receive intramuscular injections once monthly or every two months. The ATLAS and FLAIR Phase 3 trials confirmed non-inferiority to daily oral regimens for virologically suppressed adults.
In 2026, research is focused on expanding eligibility (current restrictions exclude patients with certain resistance mutations or prior virologic failures), optimizing the every-two-months schedule, and evaluating CAB+RPV in pregnant women and adolescents. The challenge of injection-site reactions and the requirement for healthcare visits remain subjects of real-world adherence studies.
Lenacapavir: The Every-Six-Month Injection
Lenacapavir (Sunlenca, Gilead) is a first-in-class capsid inhibitor with a uniquely long half-life — it can be dosed subcutaneously just twice per year. Approved in 2022 for treatment-experienced adults with multidrug-resistant HIV, it works by disrupting multiple stages of the HIV lifecycle through binding to the viral capsid protein.
The landmark PURPOSE 1 and PURPOSE 2 trials tested lenacapavir as PrEP — HIV prevention — in high-risk populations. PURPOSE 1 (cisgender women and adolescent girls in Africa) showed 100% efficacy: zero infections in the lenacapavir group compared to background infection rates. PURPOSE 2 showed 96% efficacy in men who have sex with men and transgender individuals. These results, announced in 2024, are transformative for global prevention efforts, and access and pricing negotiations are ongoing.
Broadly Neutralizing Antibodies and Cure Research
The most ambitious HIV research in 2026 targets a functional cure — long-term viral suppression without ART. Broadly neutralizing antibodies (bNAbs) are laboratory-derived antibodies that recognize conserved epitopes on the HIV envelope, neutralizing a wide range of viral strains.
VRC01 and VRC01-class bNAbs: Early-generation bNAbs showed modest efficacy in preventing infection in AMP trials. Next-generation bNAbs (VRC07-523LS, 3BNC117-LS, 10-1074) with extended half-lives are now in combination trials. The rationale: combinations of 2–3 bNAbs targeting different epitopes may suppress viral rebound after ART interruption and potentially clear the viral reservoir over time.
Analytical Treatment Interruption (ATI) trials: Multiple studies are testing whether bNAb combinations, with or without latency-reversing agents, can maintain viral suppression after patients stop ART. A small number of "post-treatment controllers" — people who maintain viral suppression for years after stopping ART — are being studied intensively to identify what immune factors enable control.
mRNA HIV Vaccines: A New Approach
The success of mRNA COVID-19 vaccines has accelerated interest in applying the same technology to HIV. The challenge is far greater: HIV mutates rapidly, establishes a latent reservoir in resting CD4+ T cells, and has evolved mechanisms to evade the immune system that thwart conventional vaccine approaches.
Moderna and the IAVI partnership have advanced mRNA-1644, a vaccine candidate designed using germline-targeting — a strategy to activate rare B cell precursors capable of evolving into broadly neutralizing antibody producers. Phase 1 results published in 2023 showed that the vaccine successfully elicited the desired precursor B cells in 97% of recipients, a milestone that had not been achieved before. Phase 2 trials are now testing whether sequential boosting can mature these responses into broadly neutralizing antibodies. This approach, if successful, would represent a fundamentally new vaccine design strategy applicable to many pathogens.
HIV and Aging: Comorbidities in Long-Term Survivors
With effective ART, people with HIV now have near-normal life expectancy — but face accelerated aging, higher rates of cardiovascular disease, neurocognitive decline, kidney disease, and bone loss. Clinical trials in 2026 are evaluating statins for cardiovascular protection (the REPRIEVE trial showed pitavastatin reduced cardiovascular events by 35% in people with HIV), anti-inflammatory strategies targeting chronic immune activation, and interventions for HIV-associated neurocognitive disorders (HAND).
Key Takeaways
- CAB+RPV monthly/bimonthly injections are now standard options for virologically suppressed adults unable or unwilling to take daily pills.
- Lenacapavir twice-yearly injections showed near-perfect PrEP efficacy in PURPOSE trials, potentially revolutionizing HIV prevention globally.
- Broadly neutralizing antibody combinations are in ATI trials targeting functional HIV cure for the first time.
- mRNA HIV vaccines using germline-targeting have cleared a key early milestone and are advancing to Phase 2 testing.
- HIV-related aging and comorbidities — cardiovascular disease, neurocognitive decline — are major targets for new intervention trials.